Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 1.00 |
| ▸ | HPGD | P15428 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.79 |
| ▸ | TP53 | P04637 | 1/20 | 0.79 |
| ▸ | ATM | Q13315 | 1/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.58 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16333352 | 1.00 | RAB9A (1.00) | RAB9AHPGDNPC1SMN1; SMN2KMT2A | |
| SCHEMBL16334901 | 1.00 | RAB9A (1.00) | RAB9AHPGDNPC1SMN1; SMN2KMT2A | |
| SCHEMBL17661421 | 0.88 | RAB9A (0.80) | RAB9AHPGDNPC1SMN1; SMN2KMT2A | |
| SCHEMBL17661422 | 0.88 | RAB9A (0.80) | RAB9AHPGDNPC1SMN1; SMN2KMT2A | |
| SCHEMBL14160565 | 0.85 | HPGD (0.78) | RAB9AHPGDNPC1SMN1; SMN2KMT2A | |
| SCHEMBL17933815 | 0.84 | HIF1A (0.90) | RAB9AHPGDNPC1SMN1; SMN2KMT2A | |
| SCHEMBL16373566 | 0.84 | NPC1 (0.72) | RAB9AHPGDNPC1SMN1; SMN2KMT2A | |
| SCHEMBL4286612 | 0.83 | RAB9A (0.71) | RAB9AHPGDNPC1SMN1; SMN2KMT2A | |
| SCHEMBL17874048 | 0.81 | RAB9A (0.67) | RAB9AHPGDNPC1SMN1; SMN2KMT2A | |
| SCHEMBL17874024 | 0.80 | RAB9A (0.80) | RAB9AHPGDNPC1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-02 | — | — | US | claimed |
| EP-3013341-A1 | METHODS OF MODULATING CFTR ACTIVITY | Proteostasis Therapeutics, Inc. (US) | 2016-05-04 | — | — | EP | claimed |
| WO-2014210159-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2014-12-31 | — | — | WO | claimed |
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-02 | — | — | US | disclosed |
| EP-3013341-A1 | METHODS OF MODULATING CFTR ACTIVITY | Proteostasis Therapeutics, Inc. (US) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014210159-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014210159-A1 | METHODS OF MODULATING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160151335-A1 | METHODS OF MODULATING CFTR ACTIVITY | CFTR, HSP90B1, SERPINB1 | RAB9A 1564/4885HPGD 967/4885NPC1 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.